Activity of quinupristin-dalfopristin in invasive isolates of Streptococcus pneumoniae from Italy

被引:4
作者
Pantosti, A
D'Ambrosio, F
Bordi, E
d'Abusco, AS
Del Grosso, M
机构
[1] Ist Super Sanita, Batteriol & Micol Med Lab, I-00161 Rome, Italy
[2] Ist Nazl Malattie Infett Lazzaro Spallanzani, Lab Anal Clin & Microbiol, Rome, Italy
关键词
macrolides; quinupristin-dalfopristin; Streptococcus pneumoniae; streptogramins;
D O I
10.1046/j.1198-743x.2001.00298.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Eighty-five recent isolates of Streptococcus pneumoniae from patients with invasive disease were examined for their susceptibility to erythromycin, clindamycin, penicillin and quinupristin-dalfopristin by E test. A novel duplex PCR assay was used to detect the presence of the erm(B) or mef (A) genes in all of the erythromycin-resistant isolates. All of the strains tested were susceptible to the combination quinupristin-dalfopristin, regardless of their susceptibility to penicillin or to erythromycin. By duplex PCR, two-thirds of the erythromycin-resistant strains harbored erm, and one-third harbored mef. The activity of quinupristin-dalfopristin was not influenced by the genetic determinant of erythromycin resistance. The in vitro susceptibility of S. pneumoniae to quinupristin-dalfopristin is promising for future use; however, it is important to monitor the possible emergence of resistance.
引用
收藏
页码:503 / 506
页数:4
相关论文
共 22 条
[1]   Avoparcin and virginiamycin as animal growth promoters: a plea for science in decision-making [J].
Acar, J ;
Casewell, M ;
Freeman, J ;
Friis, C ;
Goossens, H .
CLINICAL MICROBIOLOGY AND INFECTION, 2000, 6 (09) :477-482
[2]   Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin) [J].
Barry, AL ;
Fuchs, PC ;
Brown, SD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) :945-946
[3]   Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci [J].
Betriu, C ;
Redondo, M ;
Palau, ML ;
Sánchez, A ;
Gómez, M ;
Culebras, E ;
Boloix, A ;
Picazo, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (07) :1838-1841
[4]   FAILURE OF PRISTINAMYCIN TREATMENT IN A CASE OF PNEUMOCOCCAL PNEUMONIA [J].
BURUCOA, C ;
PASDELOUP, T ;
CHAPON, C ;
FAUCHERE, JL ;
ROBERT, R .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1995, 14 (04) :341-342
[5]  
Dowzicky Michael, 1998, American Journal of Medicine, V104, p34S, DOI 10.1016/S0002-9343(98)00153-3
[6]   The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents:: A 6-year population-based assessment [J].
Gay, K ;
Baughman, W ;
Miller, Y ;
Jackson, D ;
Whitney, CG ;
Schuchat, A ;
Farley, MM ;
Tenover, F ;
Stephens, DS .
JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (05) :1417-1424
[7]   Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients [J].
Johnson, CA ;
Taylor, CA ;
Zimmerman, SW ;
Bridson, WE ;
Chevalier, P ;
Pasquier, O ;
Baybutt, RI .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (01) :152-156
[8]   Streptogramins: an answer to antibiotic resistance in gram-positive bacteria [J].
Leclercq, R ;
Courvalin, P .
LANCET, 1998, 352 (9128) :591-592
[9]   Macrolide resistance mechanisms and expression of phenotypes among Streptococcus pneumoniae circulating in Italy [J].
Marchese, A ;
Tonoli, E ;
Debbia, EA ;
Schito, GC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (04) :461-464
[10]  
National Committee for Clinical Laboratory Standards, 1999, M100S9 NCCLS